ONCOCEUTICS, INC.
Biotech · Acquired
ONC201, a small molecule DRD2 antagonist for oral treatment of recurrent glioblastoma and diffuse midline glioma
- Grants
- $6.6M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 23
- 10 granted · 13 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Clinical efficacy of the antitumor agent ONC201 in GBM | $210,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical efficacy of the antitumor agent ONC201 in GBM | $847,452 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical efficacy of the antitumor agent ONC201 in GBM | $552,548 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical efficacy of the antitumor agent ONC201 in GBM | $224,700 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer | $224,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma | $999,600 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer | $4,319 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer | $714,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer | $777,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma | $999,600 | |
| Federal grant | Department of Health and Human Services · Phase II · Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma | $999,250 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2953 | Stem Cell Development Fund, LLC | — | $2.8M |
| 2954 | TISSUEFORM, INC. | — | — |
| 2955 | Diasome Pharmaceuticals, Inc. | — | $50M |
| 2956 | ONCOCEUTICS, INC. | — | — |
| 2957 | INTEGRATED ANIMAL RESEARCH LLC | — | — |
| 2958 | TEZCAT Laboratories LLC | — | — |
| 2959 | Korsana Biosciences | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Impridones For Gliomasapplication
- Imipridones For Gliomasgranted
- G Protein-coupled Receptor (gpcr) Modulation By Imipridonesgranted
- 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, Salts Thereof And Methods Of Using The Same In Combination Therapyapplication
- 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, Salts Thereof And Methods Of Using The Same In Combination Therapygranted
- Imipridones For Gliomasgranted
- 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, Salts Thereof And Methods Of Using The Same In Combination Therapygranted
- Imipridones For Gliomasgranted
- 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, Analogs Thereof, And Salts Thereof And Methods For Their Use In Therapyapplication
- Imipridones For Gliomasgranted
- 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, Salts Thereof And Methods Of Using The Same In Combination Therapygranted
- 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapygranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.